IN 2008, FDA required future diabetes medications be evaluated in light of Cardiovascular risk.
GLP-1: LEADER trial - Liraglutide
DPP4i:
SGLT2I: EMPA-REG - Empagliflozin
Comparison of LEADER and EMPA-Reg here.
Overview of studies here:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment